LGND Stock Analysis: Ligand Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 6.253m USD | 12M Return: 180.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 114M
EPS Trend: -24.2%
Qual. Beats: -1
Rev. Trend: 88.2%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses biopharmaceutical assets globally. Its commercial and pipeline portfolio spans a wide range of therapeutic areas, including infectious disease, oncology, nephrology, endocrinology (such as type 1 diabetes), respiratory disease, cardiology, neurology, hepatology, ophthalmology, and rare diseases, with products like KYPROLIS, VEKLURY, TZIELD, FILSPARI, and VAXNEUVANCE licensed from or to partners worldwide.
The company was incorporated in 1987 and is headquartered in Jupiter, Florida. Ligands business model centers on out-licensing its technologies and drug candidates to larger commercial partners in exchange for milestone payments and royalties, rather than commercializing products itself. A notable proprietary platform underlying several of its partnered products is Captisol, a cyclodextrin-based formulation technology used to improve the solubility and stability of drugs such as Nexterone (amiodarone) and VEKLURY (remdesivir).
- Kyprolis and EVOMELA royalties anchor core revenue growth
- Filspari launch accelerates IgA nephropathy royalty contributions
- Acquisitive M&A strategy expands royalty and Captisol platform
| Net Income: 153.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 22.40 > 1.0 |
| NWC/Revenue: 300.5% < 20% (prev 138.1%; Δ 162.4% < -1%) |
| CFO/TA 0.08 > 3% & CFO 123.4m > Net Income 153.6m |
| Net Debt (-322.3m) to EBITDA (222.2m): -1.45 < 3 |
| Current Ratio: 21.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.9m) vs 12m ago 3.61% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 22.52% > 50% (prev 20.04%; Δ 2.48% > 0%) |
| Interest Coverage Ratio: 33.56 > 6 (EBIT TTM 187.8m / Interest Expense TTM 5.59m) |
| A: 0.54 (Total Current Assets 865.4m - Total Current Liabilities 40.7m) / Total Assets 1.53b |
| B: 0.39 (Retained Earnings 594.7m / Total Assets 1.53b) |
| C: 0.15 (EBIT TTM 187.8m / Avg Total Assets 1.22b) |
| D: 1.86 (Book Value of Equity 997.3m / Total Liabilities 534.8m) |
| Altman-Z'' = 7.79 = AAA |
| DSRI: 0.85 (Receivables 54.8m/42.8m, Revenue 274.5m/181.5m) |
| GMI: 0.99 (GM 97.32% / 98.61%) |
| AQI: 0.66 (AQ_t 0.43 / AQ_t-1 0.65) |
| SGI: 1.51 (Revenue 274.5m / 181.5m) |
| TATA: 0.02 (NI 153.6m - CFO 123.4m) / TA 1.53b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 319.43 with a total of 316,467 shares traded. Over the past week, the price has changed by +1.72%, over one month by +34.36%, over three months by +55.74% and over the past year by +180.79%.
Current recommended Stop Loss: 303.90 (which is 4.9% or 1.3 ATR below the current price).
Ligand Pharmaceuticals has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy LGND.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 277.6 | -13.1% |
P/E Trailing = 40.6793
P/E Forward = 34.965
P/S = 22.7816
P/B = 6.2677
P/EG = 1.5271
Revenue TTM = 274.5m USD
EBIT TTM = 187.8m USD
EBITDA TTM = 222.2m USD
Long Term Debt = 446.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.09m USD (from shortTermDebt, last quarter)
Debt = 457.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 5.08m
Net Debt = -322.3m USD (calculated: Debt 457.1m - CCE 779.4m)
Enterprise Value = 5.93b USD (6.25b + Debt 457.1m - CCE 779.4m)
Interest Coverage Ratio = 33.56 (Ebit TTM 187.8m / Interest Expense TTM 5.59m)
EV/FCF = 25.09x (Enterprise Value 5.93b / FCF TTM 236.3m)
FCF Yield = 3.98% (FCF TTM 236.3m / Enterprise Value 5.93b)
FCF Margin = 86.10% (FCF TTM 236.3m / Revenue TTM 274.5m)
Net Margin = 55.95% (Net Income TTM 153.6m / Revenue TTM 274.5m)
Gross Margin = unknown ((Revenue TTM 274.5m - Cost of Revenue TTM 3.81m) / Revenue TTM)
Tobins Q-Ratio = 3.87 (Enterprise Value 5.93b / Total Assets 1.53b)
Interest Expense / Debt = 1.22% (Interest Expense 5.59m / Debt 457.1m)
Taxrate = 16.94% (31.3m / 184.9m)
NOPAT = 156.0m (EBIT 187.8m * (1 - 16.94%))
Current Ratio = 18.84 (Total Current Assets 865.4m / Total Current Liabilities 45.9m)
Debt / Equity = 0.46 (Debt 457.1m / totalStockholderEquity, last quarter 997.3m)
Debt / EBITDA = -1.45 (Net Debt -322.3m / EBITDA 222.2m)
Debt / FCF = -1.36 (Net Debt -322.3m / FCF TTM 236.3m)
Total Stockholder Equity = 948.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.60% (Net Income 153.6m / Total Assets 1.53b)
RoE = 16.19% (Net Income TTM 153.6m / Total Stockholder Equity 948.3m)
RoCE = 13.46% (EBIT 187.8m / Capital Employed (Equity 948.3m + L.T.Debt 446.9m))
RoIC = 10.55% (NOPAT 156.0m / Invested Capital 1.48b)
WACC = 8.66% (E(6.25b)/V(6.71b) * Re(9.22%) + D(457.1m)/V(6.71b) * Rd(1.22%) * (1-Tc(0.17)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 5.37%
[DCF] Terminal Value 74.35% ; FCFF base≈236.3m ; Y1≈237.3m ; Y5≈251.4m
[DCF] Fair Price = 201.4 (EV 3.71b - Net Debt -322.3m = Equity 4.04b / Shares 20.0m; r=8.66% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: -24.16 | EPS CAGR: -3.14% | SUE: -3.09 | # QB: -1
Revenue Correlation: 88.16 | Revenue CAGR: 33.26% | SUE: -0.39 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.99 | Chg30d=-0.81% | Revisions=+29% | Analysts=8
EPS next Quarter (2026-09-30): EPS=2.51 | Chg30d=+0.12% | Revisions=+17% | Analysts=7
EPS current Year (2026-12-31): EPS=9.10 | Chg30d=+0.06% | Revisions=+0% | GrowthEPS=+11.9% | GrowthRev=+7.3%
EPS next Year (2027-12-31): EPS=11.32 | Chg30d=-0.34% | Revisions=-29% | GrowthEPS=+24.3% | GrowthRev=+28.8%
[Analyst] Revisions Ratio: +6% (up=8, down=7)